Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MRC Technology Launches Small Molecule Compound Library Access Scheme

Published: Thursday, September 20, 2012
Last Updated: Thursday, September 20, 2012
Bookmark and Share
Subset of compound library to be made available to academic researchers free of charge.

MRC Technology has announced the launch of a scheme under which it will provide access to a representative subset of 9,000 compounds from its 150,000 small molecule compound library to academic research institutes free of charge.

The scheme has been launched by MRC Technology to provide academics with a high quality compound library for screening, to reduce academic spend on libraries less suited to screening, and to encourage groups to tap into MRC Technology’s drug discovery expertise for research programmes.

Under the terms of the scheme, participating academics will receive the 9,000 compounds in plate format and in return MRC Technology will have first refusal on collaboration agreements for any drug development programmes resulting from screens of the compound library.

Assay data will be jointly owned by MRC Technology and the research institute, giving MRC Technology a better understanding of how its library is performing against a diverse range of targets and enabling further enhancement of the library through an iterative process.

MRC Technology’s compound library has been built and curated by its medicinal chemistry and computational chemistry scientists.

The library includes 100,000 high quality, diverse, drug-like compounds with hit-like properties, with an additional 50,000 compounds in subsets targeted to specific protein classes.

The 9,000 compounds available through the scheme have been chosen to represent a cross-section of the full library.

Institutes joining the scheme will also benefit from access to advice on suitable assay design and screening formats, and optimization of screening hits, from MRC Technology’s team of scientists.

“We have seen an increase in assay throughput within academic research institutes, due to the availability of affordable small-scale robotics,” said Justin Bryans, Director of Drug Discovery at MRC Technology.

Bryans continued, “By offering access to our compound library with no fees attached, our aim is to stimulate drug discovery within the academic field by enabling these laboratories to carry out high quality, medium throughput screens and to potentially further develop any hits in collaboration with MRCT.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MRC Technology and Yabao Pharmaceuticals Announce Exclusive Partnership
Partnership in China to develop novel therapeutics for Parkinson’s disease.
Friday, November 28, 2014
Charities Pledge to Inject Millions to Jump Start Drug Development for Brain Diseases
MRC Technology to lead Neurodegeneration Medicines Acceleration Programme to uncover promising drugs in pharma libraries.
Tuesday, November 18, 2014
MRC Technology and Proximagen Collaborate
Project will investigate a small molecule solution for Macrophage migration inhibitory factor.
Monday, October 13, 2014
MRC Technology Sells its MCRs Programme to Pfizer
Small molecules developed in collaboration with Queen Mary University of London.
Thursday, June 19, 2014
MRC Technology, Daiichi Sankyo form Drug Discovery Collaboration
Initiative brings together global expertise to streamline drug discovery.
Wednesday, May 14, 2014
MRC Technology and EMBLEM Collaborate to Streamline Drug Development
Initiative strengthens drug development and commercialization network.
Monday, April 15, 2013
MRC Technology Forms Alliance with World Leading Translational Research Centres
The aim of this alliance is to strengthen the international academic and/or not-for-profit drug development and commercialization network.
Monday, January 21, 2013
MRC Technology and CAS Collaborate to Identify New Targets for Drug Discovery
Initiative brings together global expertise to streamline drug discovery.
Friday, November 30, 2012
Scientific News
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Reprogramming Scorpion Venom
‘Twist of nature’ neutralizes toxin.
Tailoring a Suit for Tumor-Penetrating Cancer Meds
For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body.
Resurrecting an Abandoned Drug
Previously discarded drug shows promise in helping human cells in a lab dish fight off two different viruses.
Safer, Cheaper, Greener and More Efficient System for Organic Synthesis
The new medium not only supports organic synthesis it also produces considerably higher yields of product than pure organic solvents.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Collaboration to Develop Cancer Therapeutics
Major license agreement with Merck, enabled by Blavatnik Biomedical Accelerator, aims to develop therapy for most common form of acute leukemia.
Faster UVA Molecular Analysis Technology
There are people in the world – chemical engineers, astronomers, national defense scientists investigating an explosion – who need to know just what something is made of, down to the molecular level.
Scientists Synthesize Anti-Cancer Agent
A team led by Rice University synthetic organic chemist K.C. Nicolaou has developed a new process for the synthesis of a series of potent anti-cancer agents originally found in bacteria.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!